Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-01
2011-03-01
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252130, C514S278000, C514S447000, C540S575000, C544S359000, C546S019000, C549S068000
Reexamination Certificate
active
07897596
ABSTRACT:
The present invention provides compounds of formula (I)wherein R1, R2, R3, R4and Q have a meaning as defined herein in the specification. The compounds of formula (I) are allosteric modulators of the A1adenosine receptor and, thus, may be employed for the treatment of conditions mediated by the A1adenosine receptor. Accordingly, the compounds of formula (I) may be employed for treatment of pain, in particular, chronic pain such as neuropathic pain; cardiac disease or disorder such as cardiac disarrhythmias, e.g., peroxysmal supraventricular tachycardia, angina, myocardial infarction and stroke; neurological disease or injury; sleep disorder; epilepsy; and depression.
REFERENCES:
patent: 5332732 (1994-07-01), Scott et al.
patent: 5750728 (1998-05-01), Wagner et al.
patent: 5939432 (1999-08-01), Baraldi
patent: 6177444 (2001-01-01), Baraldi
patent: 6194449 (2001-02-01), Baraldi
patent: 6323214 (2001-11-01), Baraldi
patent: 6713638 (2004-03-01), Linden et al.
patent: 6727258 (2004-04-01), Baraldi
patent: 7019027 (2006-03-01), Linden et al.
patent: 7112607 (2006-09-01), Baraldi
patent: 2008/0125438 (2008-05-01), Baraldi et al.
MedicineNet.Com; Pain Management information.
Pagonopoulou et al., Modulatory role of adenosine and its receptors in epilepsy: Possible therapeutic approaches; Neuroscience Research, issue 1, Sep. 2006.
Gutiérres-de-Terán et al., “Novel Approaches for Modeling of the A1Adenosine Receptor and Its Agonist Binding Site”, PROTEINS: Structure, Function, and Bioinformatics, 2004, 54, 705-715.
Baraldi et al., “Synthesis and Biological Effects of Novel 2-Amino-3-naphthoylthiophenes as Allosteric Enhancers of the A1Adenosine Receptor”,J. Med. Chem. 2003, 46, 794-809.
Baraldi et al., “Synthesis of 2-amino-3-heteroaroylhtiophenes and evaluation of their activity as potential allosteric enhancers at the human A1receptor”,European J. Med. Chem. 2004, 39, 855-865.
Romagnoli et al., “Synthesis and Biological Evaluation of Allosteric A1-Adenosine Receptor Modulators Structurally Related to (2-Amino-4,5,6,7-tetrahydro-benzo[b]thiophen-3-yl)-(4-chloro-phenyl)-methanone, a Potent Compound Useful to Reduce Neuropathic Pain”,Med. Chem. Res. 2005, 14(3), 125-142.
Romagnoli et al., “Synthesis and Biological Evaluation of 2-Amino-3-(3′,4′,5′-trimethoxybenzoyl)-5-aryl Thiophenes as a New Class of Potent Antitubulin Agents”,J. Med. Chem. 2006, 49, 3906-3915.
Baraldi Pier Giovanni
Moorman Allan R.
Romagnoli Romeo
King Pharmaceuticals Research & Development, Inc.
Kukkola Paivi
Sackey Ebenezer
Wilson James O
LandOfFree
Allosteric modulators of the A 1 adenosine receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Allosteric modulators of the A 1 adenosine receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Allosteric modulators of the A 1 adenosine receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2727770